Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

Quotient Bioresearch Ltd.. (4/1/10). "Press Release: Quotient Bioresearch Highlights Enhanced Benefits of 14C Radiolabelled Stuides via Expert Webinar Series". Cambridgeshire.

Organisations Organisation Quotient Bioresearch Ltd.
  Group Quotient Bioresearch (Group)
  Organisation 2 University of Washington
Products Product radiolabeling service
  Product 2 orbitrap mass spectrometer
Person Person Rettie, Alan (Univ Washington 201004 Professor Dept of Medical Chemistry)
     


Quotient Bioresearch ("Quotient"), a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, announces a new educational webinar series entitled "14C Enabled Drug Development in Pharmaceutical R&D." The webinars will consist of scientific presentations from industry experts focused on a broad range of drug development activities that can be enhanced by 14C radiolabelled studies. To register please visit Synthesis-to-Clinic

The webinar series begins April 27 and runs during May and early June 2010. Each of the four webinars will cover specific topics: Metabolism; Species and Interspecies Dependent Metabolism; ivPK and Absolute Bioavailability; and Quotient's new Synthesis-to-Clinic platform. All four webinars are free of charge to attend and will also be available to view on demand after the event.

Each webinar will run twice a day at the following times:

7am and 9am Pacific Time/ 10am and 12pm Eastern Time/ 3pm and 5pm UK


Webinar 1: Metabolism, Tuesday 27 April

Professor Tom Baillie, Dean of the School of Pharmacy at the University of Washington and formerly Global VP Drug Metabolism and Pharmacokinetics with Merck, will discuss how the FDA MIST and ICH M3(r2) guidelines encourage metabolism investigations earlier than ever in drug development. The presentation will look at how industry is approaching this through innovative study designs and use of new technologies such as AMS (Accelerator Mass Spectrometry) and Orbitrap™ to enhance the information that can be generated during metabolism studies. The webinar will explore future approaches to conducting metabolism studies.


Webinar 2: Inter and Intra-species Differences in Drug Metabolism, Tuesday 11 May

Professor Alan Rettie, Chairman, Department of Medicinal Chemistry, University of Washington, will explore the impact of inter-species differences on metabolism studies and the impact of inter-species genetic polymorphisms on metabolism. The presentation will also provide case studies to highlight notable cases of metabolism directing the individual response.


Webinar 3: ivPK & Absolute Bioavailability, Tuesday 25 May

Dr. Bob Ings, RMI Pharmacokinetics & ex VP DMPK Roche Palo Alto, will illustrate how the routine use of iv microtracer dosing can enhance drug development and discuss what the data offer in terms of understanding absolute bioavailability, clearance characteristics and drug performance.


Webinar 4: Synthesis-to-Clinic Platform, Tuesday 8 June

The final presentation will explain how the themes discussed in the first three webinars can be comprehensively addressed by the services available through Quotient's Synthesis-to-Clinic platform. Case histories will be used to showcase recent applications of the Synthesis-to-Clinic platform and there will also be a Q&A of key topics of interest raised throughout the webinar series.


Quotient's innovative Synthesis-to-Clinic capability is a fully integrated service built on best-in-class technologies and capabilities from custom synthesis of radiolabelled compounds through to drug metabolism and clinical ADME studies. This integrated service simplifies the procurement of regulatory and non-regulatory studies, resulting in shorter development times and efficiencies. The complete project is coordinated through a single project manager, removing an extensive vendor management burden.

To register for the free, on demand webinars, please visit Synthesis-to-Clinic. To learn more about how Quotient can add value to your development programmes please contact us.

Orbitrap is a registered trademark of Thermo Fisher Scientific.

   
Record changed: 2016-03-19

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for Quotient Bioresearch (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px